Viscira, a leading provider of interactive, new-media communication and technology solutions for the life sciences industry, today announced strong operating results for the 2012 fiscal year. Overall, the company realized a nearly 50 percent increase in annual gross revenue over its 2011 financial performance.
This strong growth follows on the heels of a more than 50 percent increase in annual gross revenue in the prior year. Additionally, the company continued to maintain its solid profitability metrics with minimal debt on the balance sheet.
During 2012, Viscira added several major new clients, including GlaxoSmithKline, Biogen Idec, Novo Nordisk, and Quest Diagnostics, to its roster of prominent life sciences customers. The company also continued to expand its volume of business with existing clients such as Genentech-Roche, Johnson & Johnson, Bristol-Myers Squibb, and Novartis.
Viscira’s growth has been driven by increasing demand across the company’s entire portfolio of interactive solutions and software products, including its online speaker portal (OSP) and interactive presentation builder (IPB) platforms, 3D mechanism of action animations, and KOL video presentation modules. Demand for the company’s distinctive sales and educational applications for the iPad also grew significantly over the period.
In addition to increasing company revenue, Viscira released several new products, added key staff in important functional areas such as software development and business development, accelerated R&D activities, expanded to a new office space in NYC, and launched a new corporate website, among many other achievements realized through the year. Additionally, the company added two new patent filings to its growing patent portfolio.
“We are very satisfied with what our team was able to achieve in 2012 through their hard work and dedication,” commented Dave Gulezian, President & CEO of Viscira. “It’s exciting to see that our clients continue to respond in such a positive way to our ongoing product innovation and consistent delivery performance. We look forward to our continued growth and improvement as a company in 2013.